Figure 1.
Figure 1. Late mortality after BMT. (A) Late mortality in 854 individuals who had survived 2 or more years after autologous BMT for hematological malignancies. Median age at BMT was 36.5 years and the median length of follow-up was 7.6 years. Overall survival was 68.8% at 10 years. Adapted from Bhatia et al.12 (B) Late mortality in 1479 individuals who had survived 2 or more years after allogeneic BMT. Median age at BMT was 25.9 years and median length of follow-up was 9.5 years. Conditional survival probability at 15 years was 80.2 years for those who remained disease-free at entry into the cohort. Adapted from Bhatia et al.13

Late mortality after BMT. (A) Late mortality in 854 individuals who had survived 2 or more years after autologous BMT for hematological malignancies. Median age at BMT was 36.5 years and the median length of follow-up was 7.6 years. Overall survival was 68.8% at 10 years. Adapted from Bhatia et al.12  (B) Late mortality in 1479 individuals who had survived 2 or more years after allogeneic BMT. Median age at BMT was 25.9 years and median length of follow-up was 9.5 years. Conditional survival probability at 15 years was 80.2 years for those who remained disease-free at entry into the cohort. Adapted from Bhatia et al.13 

Close Modal

or Create an Account

Close Modal
Close Modal